PT1223966E - Utilizacao do gdnf para tratamento de defeitos na cornea - Google Patents

Utilizacao do gdnf para tratamento de defeitos na cornea

Info

Publication number
PT1223966E
PT1223966E PT00983097T PT00983097T PT1223966E PT 1223966 E PT1223966 E PT 1223966E PT 00983097 T PT00983097 T PT 00983097T PT 00983097 T PT00983097 T PT 00983097T PT 1223966 E PT1223966 E PT 1223966E
Authority
PT
Portugal
Prior art keywords
gdnf
cornea
defects
take
agonist
Prior art date
Application number
PT00983097T
Other languages
English (en)
Inventor
Michael Paulista
Michael Hanke
Friedrich Kruse
Jens Pohl
Original Assignee
Biopharm Ges Biotechn Entwickl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biopharm Ges Biotechn Entwickl filed Critical Biopharm Ges Biotechn Entwickl
Publication of PT1223966E publication Critical patent/PT1223966E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
PT00983097T 1999-10-29 2000-10-30 Utilizacao do gdnf para tratamento de defeitos na cornea PT1223966E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99121597 1999-10-29

Publications (1)

Publication Number Publication Date
PT1223966E true PT1223966E (pt) 2003-09-30

Family

ID=8239299

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00983097T PT1223966E (pt) 1999-10-29 2000-10-30 Utilizacao do gdnf para tratamento de defeitos na cornea

Country Status (11)

Country Link
US (1) US20030166537A1 (pt)
EP (1) EP1223966B1 (pt)
JP (1) JP2003512433A (pt)
AT (1) ATE238806T1 (pt)
AU (1) AU1997501A (pt)
CA (1) CA2385929A1 (pt)
DE (1) DE60002496T2 (pt)
DK (1) DK1223966T3 (pt)
ES (1) ES2198367T3 (pt)
PT (1) PT1223966E (pt)
WO (1) WO2001030375A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
FR2825273B1 (fr) * 2001-05-29 2006-11-24 Oreal Composition pour le traitement des signes cutanes du vieillissement
US20050222070A1 (en) * 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
ES2328640T3 (es) 2003-04-18 2009-11-16 Biogen Idec Ma Inc. Neublastina conjugada con un polimero glicosilada.
WO2004108760A2 (en) 2003-06-10 2004-12-16 Nsgene A/S Improved secretion of neublastin
ATE435026T1 (de) 2003-11-27 2009-07-15 Develogen Ag Verfahren zur prävention und behandlung von diabetes mit neurturin
CA2556923A1 (en) * 2004-02-20 2005-09-09 Rinat Neuroscience Corp. Methods of treating obesity or diabetes using nt-4/5
EP2075254A1 (en) 2004-03-30 2009-07-01 NsGene A/S Therapeutic use of a growth factor, NsG33
PT1786454E (pt) * 2004-08-19 2010-08-18 Biogen Idec Inc Variantes de neublastina
CN101123978B (zh) 2004-08-19 2012-12-12 比奥根艾迪克Ma公司 神经胚素变体
TW200808352A (en) * 2006-02-02 2008-02-16 Rinat Neuroscience Corp Methods for treating unwanted weight loss or eating disorders by administering a TRKB agonist
EP1988920A1 (en) * 2006-02-02 2008-11-12 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkb antagonist
TWI501774B (zh) * 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
EP1993590B1 (en) * 2006-03-01 2013-12-25 Biogen Idec MA Inc. Compostions and methods for administering gdnf ligand family proteins
WO2008070513A1 (en) * 2006-12-01 2008-06-12 Alcon Research, Ltd. Modulation of polysialylated neural adhesion molecules (psa-ncam) as a regulator of ocular disease
KR20090091181A (ko) * 2006-12-20 2009-08-26 리나트 뉴로사이언스 코퍼레이션 자가면역 장애의 치료를 위한 티로신 수용체 키나아제 ｂ 작용제
TWI445544B (zh) 2007-05-01 2014-07-21 Biogen Idec Inc 增進血管形成之組合物及方法
WO2009011892A2 (en) * 2007-07-18 2009-01-22 Boston Biomedical Research Institute Use of suif proteins and heparan sulfate in gdnf-dependent neural innervation and protection
US20110135648A1 (en) * 2007-08-08 2011-06-09 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
WO2010086828A2 (en) * 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
JP5429865B2 (ja) * 2009-09-15 2014-02-26 学校法人日本大学 生体外創傷治癒試験用用具または創傷作製方法
EP2968462B1 (en) 2013-03-15 2020-12-23 The Jackson Laboratory Methods for promoting wound healing and hair growth
CA2919316C (en) 2013-07-30 2021-08-10 Kyoto Prefectural Public University Corporation Corneal endothelial ecm therapeutic medicaments
CN107137698A (zh) * 2017-03-03 2017-09-08 北京大学第三医院 一种包含gdnf的用于治疗角膜上皮损伤的药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733875A (en) * 1994-11-15 1998-03-31 Amgen Inc. Methods of using GDNF as a neuroprotective agent
US5837681A (en) * 1996-02-23 1998-11-17 Amgen Inc. Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US5882923A (en) * 1996-06-27 1999-03-16 Sariola; Hannu Glial cell line-derived neurotrophic factor regulation of ureteric budding and growth
EP1010432A4 (en) * 1997-01-23 2004-03-10 Sumitomo Pharma REMEDIES FOR DIABETES

Also Published As

Publication number Publication date
WO2001030375A2 (en) 2001-05-03
DK1223966T3 (da) 2003-08-18
AU1997501A (en) 2001-05-08
CA2385929A1 (en) 2001-05-03
EP1223966A2 (en) 2002-07-24
US20030166537A1 (en) 2003-09-04
WO2001030375A3 (en) 2002-03-21
ATE238806T1 (de) 2003-05-15
ES2198367T3 (es) 2004-02-01
JP2003512433A (ja) 2003-04-02
DE60002496T2 (de) 2004-03-25
DE60002496D1 (de) 2003-06-05
EP1223966B1 (en) 2003-05-02

Similar Documents

Publication Publication Date Title
PT1223966E (pt) Utilizacao do gdnf para tratamento de defeitos na cornea
DE60207198D1 (de) Transplantate für die wiederherstellung von osteochondralen schäden
DE69739169D1 (de) Auf temperatur ansprechendes gel zur verzögerten freisetzung von proteinarzneistoffen
BR0312563A (pt) Comprimido de lasofoxifeno e seu revestimento
SV2002000245A (es) Oxazolidinonas substituidas y su uso ref. lea 34122-sv
ES2179910T3 (es) Modificacion cristalina del cdch, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
PT1061940E (pt) Utilizacao de foliestatina para a producao de um medicamento para o tratamento de disturbios relacionados com os musculos
DE60023600D1 (de) Replizierende retrovirale Konstrukte, ihre Herstellung und Verwendungen für den Gentransfer
ES2183510T3 (es) Composiciones de proteinas de matriz para la cicatrizacion de heridas.
US10329327B2 (en) Tricalcium phosphate binding peptides and uses thereof
ATE211391T1 (de) Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
DE60137978D1 (de) Zusammensetzung zur förderung des haarwachstums
ES2166401T3 (es) Nuevo procedimiento para la produccion de proteina dimera biologicamente activa.
MXPA04003526A (es) Composicion y metodo para el tratamiento de la diabetes.
PT1165544E (pt) 1,4-di-hidroindeno¬1,2-c|pirazoles substituidos como inibidores de tirosina-quinase
ATE464878T1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
MX9301535A (es) Material proteinaceo biologicamente activo aislado y purificado.
DE19781038T1 (de) Keratinozytenwachstumsfaktor-2-Produkte
DE69817180D1 (de) Zns neuroregenerative zusammensetzungen und deren verwendungen
EP1801232A4 (en) METHOD FOR SORTING TRANSMEMBRANE ENZYME INHIBITOR SUBSTANCE
AR002272A1 (es) Uso de amidas de fenilciclohexilcarboxilicos
WO2001068643A3 (fr) Nouveaux derives heterocycliques ou benzeniques de l'acide lipoique, leur preparation et leur application a titre de medicaments
DE69939586D1 (de) Inhibitoren für die gefässneubildung
NO20032977L (no) Anvendelse av biologisk materiale inneholdende tredimensjonale oppsatsstrukturer av hyaluronsyrederivater for fremstilling av implantater i forbindelse med artroskopi.
IL145403A0 (en) Fragments of virus protein 2 or 3 of the polyoma virus, use for transporting active ingredients